Fig. 1. Study design. a, Dose escalation to 80 mg adalimumab (ADA) every other week (EOW) at/after week 12 for disease flares/non-response. OL, Open-label.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.